Exon 20 Insertions: Approved Options, New Data, and the Oral Agent Landscape

In this segment, the panel turns to EGFR exon 20 insertion mutations, a subgroup that has historically been underserved by the major advances in the classical EGFR mutation space and that requires comprehensive testing to identify reliably. You will hear why hot-spot panels miss a meaningful proportion of these mutations and why broad next-generation sequencing is essential. The panel reviews the approved frontline combination regimen for this population, presents the final overall survival analysis being reported at this year's World Conference on Lung Cancer, and discusses what the magnitude of benefit means in a disease where historical survival expectations have been poor. The discussion also covers the oral agent landscape for exon 20 insertions, including the practical and access challenges that have complicated the use of one recently approved option in the United States.